

AD _____

Award Number: DAMD17-03-1-0244

TITLE: ER(alpha) and ErbB-2 Cross-Talk in Mammary Tumorigenesis
and Metastasis

PRINCIPAL INVESTIGATOR: William J. Muller, Ph.D.

CONTRACTING ORGANIZATION: McGill University
Montreal H3A 2T5 Canada

REPORT DATE: April 2004

TYPE OF REPORT: Annual

PREPARED FOR: U.S. Army Medical Research and Materiel Command
Fort Detrick, Maryland 21702-5012

DISTRIBUTION STATEMENT: Approved for Public Release;
Distribution Unlimited

The views, opinions and/or findings contained in this report are those of the author(s) and should not be construed as an official Department of the Army position, policy or decision unless so designated by other documentation.

20040802 059

REPORT DOCUMENTATION PAGEForm Approved
OMB No. 074-0188

Public reporting burden for this collection of information is estimated to average 1 hour per response, including the time for reviewing instructions, searching existing data sources, gathering and maintaining the data needed, and completing and reviewing this collection of information. Send comments regarding this burden estimate or any other aspect of this collection of information, including suggestions for reducing this burden to Washington Headquarters Services, Directorate for Information Operations and Reports, 1215 Jefferson Davis Highway, Suite 1204, Arlington, VA 22202-4302, and to the Office of Management and Budget, Paperwork Reduction Project (0704-0188), Washington, DC 20503

1. AGENCY USE ONLY (Leave blank)		2. REPORT DATE April 2004	3. REPORT TYPE AND DATES COVERED Annual (31 Mar 2003 - 30 Mar 2004)
4. TITLE AND SUBTITLE ER(alpha) and ErbB-2 Cross-Talk in Mammary Tumorigenesis and Metastasis			5. FUNDING NUMBERS DAMD17-03-1-0244
6. AUTHOR(S) William J. Muller, Ph.D.			
7. PERFORMING ORGANIZATION NAME(S) AND ADDRESS(ES) McGill University Montreal H3A 2T5 Canada E-Mail: muller@molonc.mcgill.ca			8. PERFORMING ORGANIZATION REPORT NUMBER
9. SPONSORING / MONITORING AGENCY NAME(S) AND ADDRESS(ES) U.S. Army Medical Research and Materiel Command Fort Detrick, Maryland 21702-5012			10. SPONSORING / MONITORING AGENCY REPORT NUMBER
11. SUPPLEMENTARY NOTES Original contains color plates: ALL DTIC reproductions will be in black and white			
12a. DISTRIBUTION / AVAILABILITY STATEMENT Approved for Public Release; Distribution Unlimited			12b. DISTRIBUTION CODE
13. ABSTRACT (Maximum 200 Words) The interaction between growth factor and steroid hormone receptors may play a critical role in the breast cancer progression. The principle objective of this proposal is to elucidate the <i>in vivo</i> importance of cross-talk between estrogen and ErbB-2 signaling pathways. We first plan to establish transgenic mice that express both an constitutively active estrogen receptor and its co-activator in the mammary epithelium. To accomplish this objective, we will derive separate strains of transgenic mice that carrying either a constitutively activated ER or its co-activator AIB1 under the transcriptional control of the mouse mammary tumor virus (MMTV) promoter enhancer. Once these transgenic strains have been derived we will assess whether activation of estrogen signaling pathway can either positively or negatively influence ErbB-2 mediated tumor progression by interbreeding these strains to separate strains of transgenic mice expressing an activated erbB-2 oncogene in the mammary epithelium. Because activation of estrogen signaling pathway is known to influence the transcriptional activity of the erbB-2 promoter, we plan to use a unique ErbB-2 mammary tumor model in which mammary epithelial expression of the ErbB-2 oncogene is under the transcriptional control of the endogenous ErbB-2 promoter. The results of these studies will provide important insight into these crucial signaling pathways in breast cancer progression.			
14. SUBJECT TERMS Breast Cancer			15. NUMBER OF PAGES 11
			16. PRICE CODE
17. SECURITY CLASSIFICATION OF REPORT Unclassified	18. SECURITY CLASSIFICATION OF THIS PAGE Unclassified	19. SECURITY CLASSIFICATION OF ABSTRACT Unclassified	20. LIMITATION OF ABSTRACT Unlimited

NSN 7540-01-280-5500

Standard Form 298 (Rev. 2-89)
Prescribed by ANSI Std. Z39-18
298-102

Table of Contents

Cover.....	
SF 298.....	
Table of Contents.....	2
Introduction.....	3
Body.....	3
Key Research Accomplishments.....	9
Reportable Outcomes.....	
Conclusions.....	9
References.....	10
Appendices.....	

Introduction

The induction of human breast cancer involves the complex interplay of hormonal, and genetic events. There is an extensive body of literature implicating the activation of ER α in induction of sporadic breast cancer. Despite the importance of this signaling pathway, there are relative few studies that have directly assessed the ER α signaling axis in tumor progression. Another important genetic event in sporadic breast cancer is the amplification and consequent overexpression of erbB-2 gene (7, 8). Although amplification and elevated expression of erbB-2 has been established as an important event in sporadic breast cancer, comparatively little is known concerning the interaction of erbB-2 and ER α in sporadic breast cancer.

Activation of receptor tyrosine kinases such as erbB-2 can lead to the stimulation of downstream signaling pathways such as the MAP kinase pathway. In turn activated MAP kinase can result in the direct phosphorylation of ER α and stimulation of its transcriptional activity (3). Additional evidence supporting the concept that erbB-2 signaling may influence ER α function stems from the recent observation that c-Src and ER α can form specific complexes that result in the activation of the MAP kinase cascade (4). Because activation of the c-Src kinase appears to be an important signaling pathway in ErbB-2 mammary tumor progression (4-6), c-Src may play an important role in the crosstalk between ER α and ErbB-2 receptors.

Although the data reviewed above argue that complex interaction exists between ER α and ErbB-2 signaling, comparatively little is known concerning this interaction in mammary tumor progression. The principle focus of this application is to explore the significance of the ER α signaling axis in ErbB-2 mammary tumor progression. To accomplish this, we have derived separate strains of transgenic mice that express a constitutively activated ER α or its cognate co-activator AIB1 in the mammary epithelium. To assess the consequences of the activation of ER α signaling pathway on ErbB-2 induced mammary tumor progression, we plan to interbreed these strains to a transgenic mouse model that expresses an activated erbB-2 under the transcriptional control of endogenous erbB-2 promoter.

Body

Establishment of transgenic mice that express a constitutively activated ER α in the mammary epithelium.

Given the potential importance of ER α in sporadic breast cancer, one of our first goals was to generate transgenic mice that express an activated version of ER α in mammary epithelium. The activated version of ER α possesses an asparagine substitution at tyrosine 537 that mimics a ligand activated ER α (9). To accomplish this, a cDNA encoding the activated ER α was cloned into an MMTV based expression plasmid (Figure 1A) and microinjected into FVB/N one cell mouse embryos. A total of eight founder animals were generated.




Figure 1 : Schematic representations of the MMTV-activated ER α (A) and MMTV- AIB1 (B).

To assess whether transgenic strains were expressing the transgene in the mammary epithelium, RNA was extracted from either virgin or lactating mammary epithelium from the various progeny and quantitative real time RT-PCR was performed on RNA samples with primers directed to the SV40 component of the transgene. The results revealed that of the eight founder strains tested, three of the strains expressed detectable levels of the activated ER transgene (Figure 2). In all three cases the lactating epithelial sample expressed significantly higher levels of the MMTV/ER α transgene. In particular the 02-351-5 strain expressed 8 fold elevated levels of ER α transgene compared to the two other expressing strains.

- 3 founders express MMTV-activated ERalpha :
 - _ 02-351-5 (virgin and lactating mammary gland)
 - _ 02-347-2 (lactating mammary gland)
 - _ 02-346-1 (lactating mammary gland)




Figure 2 : Quantification of MMTV-activated ER α expression by Real-Time RT-PCR using primers directed to the SV40 component of the transgene.

To explore whether ectopic expression of ER α interfered with normal mammary gland development, we performed wholemount and histological analyses on 5 months old virgin mammary epithelium derived from the 02-351-5 founder strain. The results showed that despite the elevated expression of activated ER α observed in the mammary epithelium of these transgenic strains, both wholemount and histological analyses of mammary glands revealed no overt signs of hyperplasia (Figure 3). These observations suggest that at least at these stages of virgin mammary development, ectopic expression of activated ER α is not associated with any obvious mammary gland abnormalities. However wholemount examination of lactating mammary glands revealed a potential defect in lactating glands.




Figure 3 : Whole mount and histological analysis of virgin mammary glands. (A, B) Whole mount preparations of virgin glands from 5 months old control (A) and MMTV-activated ER α expressing (B) mice. (C, D) H&E stained sections of virgin glands from 5 months old control (C) and MMTV-activated ER α expressing (D) mice.

Although lobular alveolar development and milk production could be detected in the transgenic mammary glands (Figure 4C), closer examination of the wholemounts revealed regions of delayed alveolar development compared to wild type controls (compare Figure 4B to Figure 4D). These observations suggest that ectopic expression of ER α may impact on the latter stages of mammary differentiation.




Figure 4 : Whole mount preparations of lactating mammary glands from first day post-partum control (A,B) and MMTV-activated ER α expressing (C,D) mice. Mice used in this experiment were age-matched and uniparous.

To confirm that expression of the activated ER α in the mammary epithelium was confined to the mammary epithelial cells, we also performed immunohistochemical staining on virgin mammary glands from the ER α expressing strain. Because the antibodies were directed to the human ER α and do not cross react with the endogenous mouse ER α receptor, we can specifically detect expression of transgene driven in ER α in histological sections. Examination of virgin glands revealed uniform staining of ER α in the transgenic virgin mammary gland (Figure 5C and 5D). By contrast examination of control virgin gland failed to reveal any ER α positive cells (Figure 5A and 5B). In addition to the observed uniform and elevated expression of ER α , higher magnification of the transgenic mammary glands revealed that activated ER α was localized primary to its expected nuclear localization (Inset , Figure 5D).




Figure 5 : Immunostaining of ER α on paraffin embedded sections of virgin mammary glands from 5 month old control (A,B) and MMTV-activated ER α expressing (C,D) mice. The sections were stained with a mouse monoclonal antibody specific for human estrogen receptor alpha (Novocastra, NCL-ER-6F11) followed by a goat anti-mouse HRP labeled secondary antibody. Inset in D shows a higher magnification of ER α nuclear staining. Representative cells exhibiting nuclear staining for ER α are indicated by black arrows.

Given the elevated and mammary specific expression of ER α observed in this MMTV/ER α transgenic strains, we have now generated a cohort of 20 virgin female transgene carriers that will be monitored for the occurrence of mammary tumors over the next year. In addition we have also initiated interbreeding of this MMTV/ER α strain with separate strain of transgenic mice expressing a Cre inducible activated erbB-2 under its endogenous promoter (2). Once the appropriate cohort of female animal co-expressing activated erbB-2 and ER α have generated, we will monitor these mice for the occurrence of mammary tumors. This set of experiments should allow us to ascertain whether ectopic expression of activated ER α can impact on ErbB-2 induced mammary tumor progression.

Another important goal of this research program was to generate transgenic mice that ectopically express the ER α coactivator AIB1. To this end, we have placed an HA tagged AIB1 cDNA under the transcriptional control of the MMTVpromoter (Figure 1B). Preliminary expression analyses of the mammary epithelium derived from MMTV/AIB1 founders have failed to detect any founder strains that express elevated levels of AIB. We

are in the process of generating further founder strains. Once we identified an appropriate transgene expressing strain, we will initiate interbreeding of this MMTV/AIB strain with separate MMTV/ER α and activated erbB-2 strains.

KEY RESEARCH ACCOMPLISHMENTS

1. Generation of transgenic mice expressing elevated levels activated ER α in the mammary epithelium
2. Identification of potential alveolar differentiation defect in MMTV/ER α strains
3. Generation of a cohort of virgin MMTV/ER α mice that will be monitored for tumor formation.

CONCLUSIONS

We have made substantial progress on DOD sponsored research program designed to investigate the interaction of ER α and ErbB-2 signaling pathways in mammary tumor progression. Firstly we have successfully established three independent transgenic strains that ectopically express ER α in the mammary epithelium. Using immunohistochemical staining approach we have further demonstrated that ER α is uniformly expressed in the mammary epithelium. Despite the ectopic expression of activated ER α wholemount analyses of virgin glands failed to exhibit any of evidence hyperplastic expansion. Indeed consistent with this observation, it has been reported that in normal human breast epithelium, estrogen receptor positive cell fail to proliferate (1). To confirm whether the estrogen receptor positive epithelium in transgenic strains also exhibit this proliferation block, we will perform immunohistochemical staining on these glands with a Ki67 proliferative marker. This set of experiments should allow us to assess whether, like in human breast cancer epithelial cells, activation of ER α induces a proliferative block. Should female transgenic mice eventually develop mammary tumors, we will utilize both comparative genome hybridization and gene expression profiling approaches to determine if ER α induced tumors have undergone genetic alteration that have enable them to escape this proliferative block associated with expression of ER α . Given the high levels of ER α expression observed in this strain, we will monitor the cohort of female mice from this strain for mammary tumor development. In addition, we have initiated crosses of this strain with Cre-inducible activated erbB-2 strains to explore whether elevated expression of activated ER α can influence ErbB-2 induced tumorigenesis in this transgenic mouse of human breast cancer.

Another observation that we will explore further is the aberrant alveolar differentiation observed in the MMTV/ER α strains. To explore whether ectopic expression of activated ER α can interfere with normal mammary differentiation, we will conduct wholemount and histological analyses of the mammary glands from day 5, 10 and 15 pregnant mice. To complement these histological approaches, we plan to isolate mammary gland RNA

from the contralateral fat pads and test for the expression of mammary epithelial differentiation markers such as β -casein and WAP proteins. These detailed molecular analyses should provide important insight into the potential role of ER α in mammary differentiation.

Our initial screen of MMTV/AIB founder strains as yet to reveal an adequate transgene expressor. One potential explanation for the lack of transgene expressors is that the transgene has integrated in an area of condensed chromatin. Indeed it is our experience that we have to generate 10 lines to obtain several expressing strains. Consequently, we are in the process of generating additional strains through additional rounds of microinjection. We will hopefully obtain the appropriate MMTV/AIB strains within the next few months.

REFERENCES

1. **Anderson, E., and R. B. Clarke.** 2004. Steroid receptors and cell cycle in normal mammary epithelium. *J Mammary Gland Biol Neoplasia* **9**:3-13.
2. **Andrechek, E. R., W. R. Hardy, P. M. Siegel, M. A. Rudnicki, R. D. Cardiff, and W. J. Muller.** 2000. Amplification of the neu/erbB-2 oncogene in a mouse model of mammary tumorigenesis. *Proc Natl Acad Sci U S A* **97**:3444-9.
3. **Kato, S., H. Endoh, Y. Masuhiro, T. Kitamoto, S. Uchiyama, H. Sasaki, S. Masushige, Y. Gotoh, E. Nishida, H. Kawashima, and et al.** 1995. Activation of the estrogen receptor through phosphorylation by mitogen- activated protein kinase. *Science* **270**:1491-4.
4. **Migliaccio, A., M. Di Domenico, G. Castoria, A. de Falco, P. Bontempo, E. Nola, and F. Auricchio.** 1996. Tyrosine kinase/p21ras/MAP-kinase pathway activation by estradiol- receptor complex in MCF-7 cells. *Embo J* **15**:1292-300.
5. **Muthuswamy, S. K., and W. J. Muller.** 1995. Activation of Src family kinases in Neu-induced mammary tumors correlates with their association with distinct sets of tyrosine phosphorylated proteins in vivo. *Oncogene* **11**:1801-10.
6. **Muthuswamy, S. K., P. M. Siegel, D. L. Dankort, M. A. Webster, and W. J. Muller.** 1994. Mammary tumors expressing the neu proto-oncogene possess elevated c-Src tyrosine kinase activity. *Mol Cell Biol* **14**:735-43.
7. **Slamon, D. J., Clark, G.M., Wong, S.G., Levin, W.J., Ullrich, A. and McGuire, W.L.** 1987. Human breast cancer: correlation of relapse and survival with the amplification of the HER2/neu oncogene. *Science* **235**:177-182.
8. **Slamon, D. J., Godolphin, W., Jones, L.A., Holt, J.A., Wong, S.G., Keith, D.E., Levin, W.J., Stuart, S.G., Udove, J., Ullrich, A., and Press, M.F.** 1989. Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer. *Science* **244**:707-712.
9. **Weis, K. E., K. Ekena, J. A. Thomas, G. Lazennec, and B. S. Katzenellenbogen.** 1996. Constitutively active human estrogen receptors containing amino acid substitutions for tyrosine 537 in the receptor protein. *Mol Endocrinol* **10**:1388-98.